WO2008024026A3 - Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer - Google Patents
Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer Download PDFInfo
- Publication number
- WO2008024026A3 WO2008024026A3 PCT/RU2007/000423 RU2007000423W WO2008024026A3 WO 2008024026 A3 WO2008024026 A3 WO 2008024026A3 RU 2007000423 W RU2007000423 W RU 2007000423W WO 2008024026 A3 WO2008024026 A3 WO 2008024026A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxoacridine
- acetic acid
- prostate cancer
- prophylaxis
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
The present invention provides the use of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters, in combination with antiandrogenic hormonotherapy, for the treatment, prophylaxis and relapse prevention of prostate cancer. A method of treatment or prophylaxis of prostate cancer comprises the steps of (a) administration of an effective amount of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester to a patient in need thereof and (b) hormonotherapy aimed at decreasing androgen action. Further, a method of inducing or increasing the sensitivity of prostate cancer to hormone therapy aimed at decreasing androgen action is provided, wherein the method comprises administration of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2006127809/15A RU2325160C1 (en) | 2006-07-31 | 2006-07-31 | Means of treatment and relapse prevention of prostate cancer |
RU2006127809 | 2006-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008024026A2 WO2008024026A2 (en) | 2008-02-28 |
WO2008024026A3 true WO2008024026A3 (en) | 2008-05-29 |
Family
ID=39107233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2007/000423 WO2008024026A2 (en) | 2006-07-31 | 2007-07-31 | Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2325160C1 (en) |
WO (1) | WO2008024026A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2460544C2 (en) * | 2010-11-19 | 2012-09-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ РНИОН Минздравсоцразвития России) | Method for assessing clinical effectiveness in prostate cancer |
RU2524309C1 (en) * | 2013-04-18 | 2014-07-27 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method for selecting therapeutic approach to locally advanced prostate cancer |
ES2925946T3 (en) * | 2017-09-27 | 2022-10-20 | Novel Pharma Inc | Derivative of GnRH conjugated with long-acting palmitic acid and pharmaceutical composition containing the same |
RU2730530C1 (en) * | 2019-10-29 | 2020-08-24 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | New chemical compound of l-lysine 9-oxoacridinyl-10-acetate, stimulating production of interleukin-24 and tumour necrosis factor - beta |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3681360A (en) * | 1971-04-09 | 1972-08-01 | Hoffmann La Roche | Antiviral substituted acridanones |
RU2126253C1 (en) * | 1996-06-06 | 1999-02-20 | Сурков Кирилл Геннадьевич | Agent inducing estrogen and progestine receptors |
RU2162843C2 (en) * | 1998-05-19 | 2001-02-10 | Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" | Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone |
UA11926U (en) * | 2005-07-11 | 2006-01-16 | Volodymyr Volodymyrovy Kilessa | Method for immune correction |
-
2006
- 2006-07-31 RU RU2006127809/15A patent/RU2325160C1/en active
-
2007
- 2007-07-31 WO PCT/RU2007/000423 patent/WO2008024026A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3681360A (en) * | 1971-04-09 | 1972-08-01 | Hoffmann La Roche | Antiviral substituted acridanones |
RU2126253C1 (en) * | 1996-06-06 | 1999-02-20 | Сурков Кирилл Геннадьевич | Agent inducing estrogen and progestine receptors |
RU2162843C2 (en) * | 1998-05-19 | 2001-02-10 | Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" | Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone |
UA11926U (en) * | 2005-07-11 | 2006-01-16 | Volodymyr Volodymyrovy Kilessa | Method for immune correction |
Non-Patent Citations (5)
Title |
---|
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, SURKOV K G ET AL: "[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer]", XP002474585, Database accession no. NLM9123898 * |
SZULC B ET AL: "COMPETITION OF SODIUM SALT OF 9-OXO-10-ACRIDINEACETIC ACID WITH ANALOGS DURING INDUCTION OF INTERFERON IN THE MOUSE BONE MARROW-DERIVED MACROPHAGES", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, POLISH ACADEMY OF SCIENCES, WROCLAW, PL, vol. 33, no. 219, 1985, pages 287 - 297, XP009015170, ISSN: 0004-069X * |
SZULC Z ET AL: "SYNTHESIS OF CHOLINE ESTER OF 9-OXO-10-ACRIDINEACETIC ACID AND OF CONGENERS AS POTENTIAL INTERFERON INDUCERS", POLISH JOURNAL OF CHEMISTRY, POLISH CHEMICAL SOCIETY, vol. 60, no. 4-6, 1986, pages 615 - 619, XP009015180 * |
TSYRLINA YE V ET AL: "Effect of neoadjuvant therapy with neovir on steroid hormone receptor level in endometrial carcinoma", VOPROSY ONKOLOGII (ST. PETERSBURG), vol. 47, no. 2, 2001, pages 214 - 217, XP009097909, ISSN: 0507-3758 * |
VOPROSY ONKOLOGII 1996, vol. 42, no. 6, 1996, pages 28 - 32, ISSN: 0507-3758 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008024026A2 (en) | 2008-02-28 |
RU2006127809A (en) | 2008-02-10 |
RU2325160C1 (en) | 2008-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011119857A3 (en) | Intravascular tissue disruption | |
WO2009129147A3 (en) | Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation | |
WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
WO2008075068A3 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2009129149A3 (en) | Drug depots having different release profiles for reducing, preventing or treating pain and inflammation | |
WO2008127594A3 (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
WO2008061152A3 (en) | Methods and apparatus for performing a non-continuous circumferential treatment to a body lumen | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
WO2009129210A3 (en) | Compositions and methods for treating post-operative pain using clonidine and bupivacaine | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2007143600A3 (en) | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases | |
WO2007144152A3 (en) | Extended step-down estrogen regimen | |
WO2007112357A3 (en) | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders | |
MX2012007875A (en) | Treatment method. | |
WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
WO2010022236A3 (en) | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor | |
SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
WO2012012305A3 (en) | Combination therapy using a ruthenium complex | |
WO2008024026A3 (en) | Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2011050095A3 (en) | Prevention and treatment of post-operative cognitive dysfunction (pocd) | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
WO2013055913A3 (en) | Pgam1 inhibitors and methods related thereto | |
NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor | |
WO2009155070A3 (en) | Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07808751 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07808751 Country of ref document: EP Kind code of ref document: A2 |